Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Dolastin 10 in Indolent Lymphoma and Chronic Lymphocytic Leukemia

NCT00005579 is registered in ClinicalTrials.gov with University of Vermont as lead sponsor.

NCT NCT00005579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Dolastin 10 in Indolent Lymphoma and Chronic Lymphocytic Leukemia
Lead sponsor
University of Vermont
Phase
Phase 2
Overall status
Completed
Start date
June 30, 1998
Completion date
February 28, 2003
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma